Perhaps, the down-regulation of IL-33 that was linked to the low HLA expression levels in human prostate tumours20–22 is a part of the same miR-19-mediated regulatory network, which leads to failed activation of ILC2s and poor tumour outcomes. This evidence concerns the gene IL33 and neoplasm.